Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Zhejiang Betta Pharma
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.